Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 3
2012 1
2014 1
2015 1
2018 1
2019 1
2022 4
2023 8
2024 3
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

24 results

Results by year

Filters applied: . Clear all
Page 1
Sustained S-IgG and S-IgA antibodies to Moderna's mRNA-1273 vaccine in a Sub-Saharan African cohort suggests need for booster timing reconsiderations.
Serwanga J, Ankunda V, Katende JS, Baine C, Oluka GK, Odoch G, Nantambi H, Mugaba S, Namuyanja A, Ssali I, Ejou P, Kato L; COVID-19 Immunoprofiling Team; Musenero M, Kaleebu P. Serwanga J, et al. Among authors: mugaba s. Front Immunol. 2024 Jan 31;15:1348905. doi: 10.3389/fimmu.2024.1348905. eCollection 2024. Front Immunol. 2024. PMID: 38357547 Free PMC article.
Gene expression of tight junctions in foreskin is not affected by HIV pre-exposure prophylaxis.
Webb EL, Petkov S, Yun H, Else L, Lebina L, Serwanga J, Pillay AAP, Seiphetlo TB, Mugaba S, Namubiru P, Odoch G, Opoka D, Ssemata AS, Kaleebu P, Khoo S, Martinson N, Fox J, Gray CM, Herrera C, Chiodi F. Webb EL, et al. Among authors: mugaba s. Front Immunol. 2024 Nov 6;15:1415475. doi: 10.3389/fimmu.2024.1415475. eCollection 2024. Front Immunol. 2024. PMID: 39569196 Free PMC article. Clinical Trial.
Mobilization of systemic CCL4 following HIV pre-exposure prophylaxis in young men in Africa.
Petkov S, Herrera C, Else L, Mugaba S, Namubiru P, Odoch G, Opoka D, Pillay AAP, Seiphetlo TB, Serwanga J, Ssemata AS, Kaleebu P, Webb EL, Khoo S, Lebina L, Gray CM, Martinson N, Fox J, Chiodi F. Petkov S, et al. Among authors: mugaba s. Front Immunol. 2022 Jul 27;13:965214. doi: 10.3389/fimmu.2022.965214. eCollection 2022. Front Immunol. 2022. PMID: 35967369 Free PMC article.
Bacterial microbiome and host inflammatory gene expression in foreskin tissue.
Maust BS, Petkov S, Herrera C, Feng C, Brown BP, Lebina L, Opoka D, Ssemata A, Pillay N, Serwanga J, Seatlholo P, Namubiru P, Odoch G, Mugaba S, Seiphetlo T, Gray CM, Kaleebu P, Webb EL, Martinson N, Chiodi F, Fox J, Jaspan HB; CHAPS team. Maust BS, et al. Among authors: mugaba s. Heliyon. 2023 Nov 14;9(11):e22145. doi: 10.1016/j.heliyon.2023.e22145. eCollection 2023 Nov. Heliyon. 2023. PMID: 38053902 Free PMC article.
Safety and broad immunogenicity of HIVconsvX conserved mosaic candidate T-cell vaccines vectored by ChAdOx1 and MVA in HIV-CORE 006: a double-blind, randomised, placebo-controlled phase 1 trial in healthy adults living without HIV-1 in eastern and southern Africa.
Chanda C, Kibengo F, Mutua M, Ogada F, Muturi-Kioi V, Akis Yildirim BM, Amondi M, Baines A, Basajja V, Borthwick N, Bosire K, Chambula E, Chetty P, Chinyenze K, Chirro O, Crook A, De Bont J, Fernandez N, Ejou P, Farah B, Glaze M, Gombe B, Gumbe A, Hayes P, Itwi S, Juma S, Kabarambi A, Kabengele C, Kafeero P, Kakande A, Kanungi J, Kidega W, King D, Mahira R, Malogo R, Matsoso M, Michelo C, Moyo A, Mugaba S, Mugenya I, Muhumuza P, Mujadidi YF, Muriuki M, Musale V, Mutua G, Muwowo M, Mwale F, Mwangi I, Nakimbugwe M, Namuyanja A, Nduati E, Nielsen L, Nyange J, Oino G, Okech B, Omosa-Manyonyi G, Otieno D, Palmer S, Phiri H, Ramko K, Rutishauser RL, Sayeed E, Sajabi R, Serwanga J, G-T Wee E, Wenden C, Cicconi P, Fast P, Gilmour J, Jaoko W, Kaleebu P, Kilembe W, Kuipers H, Sanders EJ, Hanke T. Chanda C, et al. Among authors: mugaba s. Lancet Microbe. 2025 Jun;6(6):101041. doi: 10.1016/j.lanmic.2024.101041. Epub 2025 May 16. Lancet Microbe. 2025. PMID: 40388952 Free PMC article. Clinical Trial.
Optimisation and Validation of a conventional ELISA and cut-offs for detecting and quantifying anti-SARS-CoV-2 Spike, RBD, and Nucleoprotein IgG, IgM, and IgA antibodies in Uganda.
Oluka GK, Namubiru P, Kato L, Ankunda V, Gombe B, Cotten M; COVID-19 Immunoprofiling Team; Musenero M, Kaleebu P, Fox J, Serwanga J. Oluka GK, et al. Front Immunol. 2023 Mar 14;14:1113194. doi: 10.3389/fimmu.2023.1113194. eCollection 2023. Front Immunol. 2023. PMID: 36999017 Free PMC article.
Pre-pandemic SARS-CoV-2-specific IFN-γ and antibody responses were low in Ugandan samples and significantly reduced in HIV-positive specimens.
Nantambi H, Sembera J, Ankunda V, Ssali I, Kalyebi AW, Oluka GK, Kato L, Ubaldo B, Kibengo F, Katende JS, Gombe B, Baine C, Odoch G, Mugaba S, Sande OJ; COVID-19 Immunoprofiling Team; Kaleebu P, Serwanga J. Nantambi H, et al. Among authors: mugaba s. Front Immunol. 2023 Apr 19;14:1148877. doi: 10.3389/fimmu.2023.1148877. eCollection 2023. Front Immunol. 2023. PMID: 37153598 Free PMC article.
Seroprevalence and durability of antibody responses to AstraZeneca vaccination in Ugandans with prior mild or asymptomatic COVID-19: implications for vaccine policy.
Serwanga J, Baine C, Mugaba S, Ankunda V, Auma BO, Oluka GK, Kato L, Kitabye I, Sembera J, Odoch G, Ejou P, Nalumansi A, Gombe B, Musenero M, Kaleebu P. Serwanga J, et al. Among authors: mugaba s. Front Immunol. 2023 May 2;14:1183983. doi: 10.3389/fimmu.2023.1183983. eCollection 2023. Front Immunol. 2023. PMID: 37205095 Free PMC article.
Short-term oral pre-exposure prophylaxis against HIV-1 modulates the transcriptome of foreskin tissue in young men in Africa.
Petkov S, Herrera C, Else L, Lebina L, Opoka D, Seiphetlo TB, Pillay AA, Mugaba S, Namubiru P, Odoch G, Ssemata AS, Serwanga J, Kaleebu P, Webb EL, Khoo S, Martinson N, Gray CM, Fox J, Chiodi F. Petkov S, et al. Among authors: mugaba s. Front Immunol. 2022 Nov 18;13:1009978. doi: 10.3389/fimmu.2022.1009978. eCollection 2022. Front Immunol. 2022. PMID: 36479111 Free PMC article. Clinical Trial.
Rapid, early, and potent Spike-directed IgG, IgM, and IgA distinguish asymptomatic from mildly symptomatic COVID-19 in Uganda, with IgG persisting for 28 months.
Serwanga J, Ankunda V, Sembera J, Kato L, Oluka GK, Baine C, Odoch G, Kayiwa J, Auma BO, Jjuuko M, Nsereko C, Cotten M, Onyachi N, Muwanga M, Lutalo T, Fox J, Musenero M, Kaleebu P; COVID-19 Immunoprofiling Team. Serwanga J, et al. Front Immunol. 2023 Mar 16;14:1152522. doi: 10.3389/fimmu.2023.1152522. eCollection 2023. Front Immunol. 2023. PMID: 37006272 Free PMC article.
24 results